13
Participants
Start Date
October 25, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
December 15, 2017
Arm A: F16IL2 in combination with paclitaxel
"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
Arm B: Paclitaxel
"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
Medical University Hospital, Graz
Herlev- University Hospital, Herlev
Saint-Louis- Hospital, Paris
Charité- Medical University Hospital, Berlin
Universitätsklinik Essen, Essen
Eberhard-Karls- University Hospital, Tübingen
ICMiD- University Hospital, Barcelona
Nottingham Trent- University Hospital, Nottingham
Collaborators (1)
Immatics Biotechnologies GmbH
INDUSTRY
Philogen S.p.A.
INDUSTRY